Related Experiment Video
Updated: Jul 18, 2025

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
Published on: August 11, 2008
Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New
Ismat Lotia Farrukh1, Nathalie Lachenal2, Malik M Adenov3
1Interactive Research and Development Pakistan, Karachi, Pakistan.
Treating pregnant women with multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) using bedaquiline and/or delamanid led to high success rates. These treatments resulted in favorable maternal outcomes and healthy neonates, showing safety during pregnancy.
Area of Science:
- Medicine
- Public Health
- Infectious Diseases
Background:
- Multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) poses a significant global health challenge.
- Treatment options for MDR/RR-TB during pregnancy have been limited, raising concerns about maternal and fetal outcomes.
Purpose of the Study:
- To evaluate the safety and efficacy of bedaquiline and/or delamanid in treating MDR/RR-TB in pregnant women.
- To assess treatment outcomes in mothers and neonates exposed to these drugs during pregnancy.
Main Methods:
- Retrospective analysis of 43 pregnant women undergoing MDR/RR-TB treatment.
- Inclusion of treatments involving bedaquiline and/or delamanid.
- Evaluation of maternal treatment outcomes and neonatal health, including birth weight and malformations.
Main Results:
- 98% of pregnant women achieved favorable treatment outcomes for MDR/RR-TB.
- In continued pregnancies (n=31), 81% resulted in live births.
- Neonatal assessment showed no reported malformations in 81% of live births, and 68% of neonates had normal birth weights.
Conclusions:
- Bedaquiline and/or delamanid are effective and safe for treating MDR/RR-TB in pregnant women.
- Treatment during pregnancy can lead to positive maternal health outcomes.
- Neonatal health appears unaffected, suggesting these drugs can be used during gestation.
More Related Videos
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Factors Affecting Drug Response: Overview
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Combined Effects of Drugs: Synergism
Such synergistic combinations...

